Claim · 2024-10-09 · publication · Stated in source · Supported

insitro's release of 9 October 2024 states that the company had raised more than $700 million in capital to date.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

insitro and Lilly Enter Strategic Agreements → states provision → company statement: more than $700 million in capital raised to date (October 2024)

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

insitro and Lilly Enter Strategic Agreementsstates provision ↓company statement: more than $700 million in capital raised to date (October 2024)

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-insitro-capital-raised-2024
Date: 2024-10-09 · publication Records dated 2024 →

Scope and limitsA cumulative company figure, "more than"; it is not a round total and does not break down by investor or instrument.

The evidence 01

primary sourceSupports the claim

insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases

insitro · 2024-10-09

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“With more than $700 million in capital raised to date”

Location in source About insitro

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: insitro
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 3f7bccc4cabec363eae2733d572858418f2c8a53606d121ca0a33e509e458645). insitro news page, dated 10/09/2024 on the page, as served on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: insitro, “insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases”, 2024-10-09.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (10 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Date of the release; a cumulative figure as the company states it at that date. The record is dated by the text’s date of publication, which is the date of its announcement.

Record ID aib-co-insitro-capital-raised-2024